How does the severity of Graves disease at presentation affect subsequent methimazole dose titration? Find out more in this month's episode!For our 75th episode, we review a forthcoming Journal of Clinical Endocrinology & Metabolism study examining whether the severity of Graves disease at presentation influences methimazole titration and treatment management. Drawing on a retrospective longitudinal cohort of 152 patients, the study provides a real-world look at antithyroid drug dosing and monitoring practices.Host Chase Hendrickson, MD, MPH, MMHC, from Vanderbilt University, is joined by new regular contributor Jonea Lim, MD, from the University of Oklahoma, and guest expert Elizabeth Pearce, MD, MSc, from Boston University. Together, they discuss “Initial disease severity and methimazole titration for Graves' disease: a retrospective longitudinal cohort study” and explore its implications for the clinical management of Graves disease.Want to learn more? Visit the Episode 75 webpage for additional resources and information about our guests and host.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related